Systematic Financial Management LP lifted its stake in shares of Endo International plc – (NASDAQ:ENDP) (TSE:ENL) by 22.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 190,550 shares of the company’s stock after acquiring an additional 35,045 shares during the period. Systematic Financial Management LP’s holdings in Endo International were worth $1,477,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in the stock. UBS Asset Management Americas Inc. raised its holdings in shares of Endo International by 4.4% during the 4th quarter. UBS Asset Management Americas Inc. now owns 221,992 shares of the company’s stock valued at $1,720,000 after buying an additional 9,438 shares during the period. Oakbrook Investments LLC purchased a new stake in shares of Endo International during the 4th quarter valued at about $133,000. LMR Partners LLP purchased a new stake in shares of Endo International during the 3rd quarter valued at about $148,000. Alps Advisors Inc. raised its holdings in shares of Endo International by 9.3% during the 3rd quarter. Alps Advisors Inc. now owns 250,511 shares of the company’s stock valued at $2,146,000 after buying an additional 21,373 shares during the period. Finally, Nisa Investment Advisors LLC purchased a new stake in shares of Endo International during the 4th quarter valued at about $236,000. Institutional investors and hedge funds own 92.54% of the company’s stock.
Several equities research analysts have issued reports on ENDP shares. B. Riley started coverage on Endo International in a report on Wednesday, February 14th. They set a “buy” rating and a $10.00 price objective on the stock. Guggenheim started coverage on Endo International in a report on Tuesday, December 12th. They set a “neutral” rating and a $8.50 price objective on the stock. Royal Bank of Canada dropped their price objective on Endo International from $9.00 to $8.00 and set a “sector perform” rating on the stock in a report on Friday, November 10th. Cantor Fitzgerald dropped their price objective on Endo International from $9.00 to $7.00 and set a “neutral” rating on the stock in a report on Friday, November 10th. Finally, Canaccord Genuity set a $7.00 price objective on Endo International and gave the stock a “hold” rating in a report on Tuesday. Three research analysts have rated the stock with a sell rating, sixteen have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $10.32.
Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Tuesday, February 27th. The company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.62 by $0.15. The company had revenue of $768.64 million during the quarter, compared to analyst estimates of $762.29 million. Endo International had a positive return on equity of 66.98% and a negative net margin of 126.97%. The business’s revenue was down 38.1% on a year-over-year basis. During the same quarter last year, the firm earned $1.77 EPS. research analysts expect that Endo International plc – will post 3.67 earnings per share for the current year.
Endo International Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Want to see what other hedge funds are holding ENDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endo International plc – (NASDAQ:ENDP) (TSE:ENL).
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.